EDAP TMS (EDAP) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EDAP TMS S.A., a leader in robotic energy-based therapies, has reported a 10.6% increase in Q2 2024 total worldwide revenue, achieving EUR 15.8 million, and a 63% growth in U.S. Focal One HIFU procedures year-over-year. The company’s growth is attributed to the expanding adoption of their Focal One technology for prostate cancer treatment, bolstered by positive clinical outcomes and a growing body of clinical evidence suggesting its effectiveness. Additionally, significant corporate developments include executive board changes and the initiation of a Phase 1-2 Clinical Trial for treating Benign Prostate Hyperplasia with Focal One Robotic HIFU.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.